Merrimack Pharmaceuticals Inc (MACK) Annual Balance Sheets

Annual · GAAP · USD millions
Access MACK quarterly Balance Sheets →
Reviewing balance sheet data across recent quarters allows users to assess how Merrimack Pharmaceuticals Inc manages assets, liabilities, and equity through different cycles.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2023)
(Dec 31 2022) (Dec 31 2021) (Dec 31 2020) (Dec 31 2019)
Assets
Cash & cash equivalent5.99
Short-term Investments, Total12.89
Cash & Short-term Investments17.00
Prepaid Expense And Other Assets Current0.31
Total Current Assets19.18
Other Assets, Noncurrent0.00
Total Assets19.19
Liabilities
Accounts Payable and Accrued Liabilities, Current LI0.44
Other Liabilities, Current0.00
Total Current Liabilities0.44
Total Long-term Debt0.00
Total Liabilities0.44
Stockholders' Equity
Common Stock Value1.34
Additional Paid In Capital Common Stock566.22
Retained Earnings / Accumulated Deficit-548.82
Other Equity0.00
Common Stockholder's Equity18.75
Total Stockholder's Equity18.75
Liabilities & Stockholder's Equity19.19
4 historic quarters locked

Sign in to unlock the full Merrimack Pharmaceuticals Inc balance sheet history.

About Merrimack Pharmaceuticals Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-24-027966

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.